thought call
rais po bullish trikafta outlook
trikafta impress start valid bull thesi stock initi quarter sale
blow away consensu stock
remark trikafta alreadi vertex bestsel drug less one partial quarter
market vertex rais expect consensu cf product sale
guidanc vs consensu view trikafta like
drive total cf upsid even cannib product inde physician survey
kol call indic intent put vast major cf patient trikafta
near futur forecast penetr prior among
patient primari patient popul age homozyg het-
min spoke manag confirm capac reimburs
headwind launch expect increas confid near
term trajectori earli launch exceed even street high expect
think truli transform natur trikafta lead rapid use nearli elig
patient drive share out-performance given increas expect
trikafta uptak along faster uptak curv higher peak potenti
well differenti growth profil revenu cagr ep
reiter buy rate list rais po
trikafta european medicin agenc ema review expect approv
trikafta phase studi age enrol vertex plan file
approv popul phase proof concept studi
antitrypsin defici enrol data expect develop
pain discontinu compani plan bring new inhibitor
clinic
updat model forecast revenu
prior respect new non-gaap
ep estim respect
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
vertex biopharmaceut compani focus
discoveri develop market new
therapi treatment cystic fibrosi
rate vertex buy differenti growth
profil compar peer compani potenti
upsid on-going trikafta launch
million
new po
given increas expect trikafta uptak along faster uptak curv
higher peak potenti well differenti growth profil
revenu cagr ep rais po prior also
reflect updat bloomberg wacc prior
price object vertex base npv analysi
forecast sale approv product kalydeco orkambi symdeko
trikafta assum wacc line peer compani
similar size risk vari termin growth rate asset base
characterist patent life given assumpt estim
valu kalydeco orkambi symdeko
trikafta net cash pipelin
risk price object payer pushback price difficulti secur
reimburs agreement particularli eu clinic trial failur new
competitor cystic fibrosi
geoff meacham herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
compani
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
